michigan semaglutide gastrointestinal obstruction class action gastric intestinal law firm louisiana semaglutide obstruction lawsuit semaglutide gi obstruction lawyer in louisiana Louisiana Ozempic Lawsuit Lawyer-150cent glp-1 bowel obstruction class action

Rather than mixing a stimulant with a peptide, it harnesses two complementary GLP-1 and GIP-receptor pathways, offering dual-agent benefits without cardiovascular risk or the short-term limitation of phentermine

Roger M

Key Highlights OPGx-BEST1 targets BEST1-associated inherited retinal diseases, including BVMD and ARB AAV-based gene therapy approach designed to deliver a functional BEST1 gene directly to retinal pigment epithelium cells Five participants enrolled in Cohort 1, including three with BVMD and two with ARB Four participants have been dosed, with the fifth scheduled for dosing this month Dominant BEST disease participants underwent in vitro confirmation to assess whether their mutations are amenable to gene augmentation Early sentinel participant data showed positive tolerability and biological activity after subretinal administration Three-month topline Cohort 1 data expected in September 2026 For BEST1-associated diseases, careful patient selection, mutation-specific validation, and multi-endpoint retinal assessments may be key to advancing gene augmentation strategies

Market Segmentation Analysis Electrolyte drinks lead the market with a 29.0% share, supported by convenience and strong consumer familiarity